口腔黏膜炎：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 德國口腔黏膜炎市場預計將從2025年的5,500萬美元成長到2035年的1.3億美元。
• 以下因素推動市場成長：
• 癌症發生率上升和強化抗癌療法的使用增加
• 擴大支持性護理和新型預防療法的引進
• 未來的成長取決於能夠預防嚴重黏膜炎和改善治療連續性的治療方法。

口腔粘膜炎概述

口腔黏膜炎是一種由細胞毒性化學療法、頭頸部放射線治療以及新近核准的靶向TROP2的抗體藥物複合體（ADCs，如datopotamab deruxtecan）引起的口腔黏膜疼痛性發炎疾病。其發病機制包括活性氧的產生、NF-κB路徑介導的發炎細胞激素放大以及黏膜屏障功能的破壞。患者最初表現為紅斑，隨後發展為疼痛性假膜性潰瘍，常導致嚴重的吞嚥困難和營養不良，常迫使患者中斷癌症治療。帕利弗明是一種重組角質細胞生長因子，用於降低接受造血幹細胞移植的骨髓惡性腫瘤患者發生嚴重口腔黏膜炎的風險。在短期化療輸注期間進行冷凍療法可減少黏膜暴露，而採用低功率雷射照射的光生物調節療法已透過多項指南證實其在預防和治療病變方面具有持續療效。症狀治療已不再局限於使用短效Lidocaine漱口水，後者無法提供持久緩解且具有全身毒性。局部疼痛管理方案主要採用長效麻醉劑，特別是口服Bupivacaine片（BupiZenge），可在數小時內提供標靶鎮痛，無需依賴全身性鴉片類藥物，同時安全地維持吞嚥和睡眠功能。嚴格的口腔衛生和多學科牙科監測對於維持黏膜完整性和最佳化癌症治療依從性仍然非常重要。

主要亮點

• 根據預測，德國新確診的口腔黏膜炎病例數將從2025年的562,562 例增加到2035年的602,105 例。
• 口腔粘膜炎是化療和放射線治療常見的併發症，嚴重影響患者的生活品質和治療順從性。
• 在嚴重的情況下，這會導致治療中斷、感染風險增加和醫療保健成本飆升。
• 目前，對於預防和治療口腔黏膜損傷的有效療法仍存在巨大的未滿足需求。

形式和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於MicrosoftExcel）
• 流行病學資料（MS Excel，互動式工具）
• 高層洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物獲得批准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

提及公司

• EpicentRx, Inc.
• OncoZenge AB
• MitoImmune Therapeutics

目錄

第1章 主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章 流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者族群。
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 依藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 目前主要療法 - 概述及關鍵意見領袖見解
• 新興療法
• 重點
• 值得關注的後期新興療法 - 概述、市場上市預期和關鍵意見領袖見解
• 值得關注的早期管道

第6章 未滿足的需求與TPP分析

• 主要未滿足需求及新興療法的未來成就
• TPP分析與KOL展望

第7章 監理與償付環境

第8章 附錄

Oral Mucositis Market Outlook

Thelansis's "Oral Mucositis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Oral Mucositis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Oral Mucositis Overview

Oral mucositis is a painful inflammatory condition of the oral mucosa arising from cytotoxic chemotherapy, head and neck radiotherapy, and newly approved TROP2-directed antibody-drug conjugates like datopotamab deruxtecan. It is driven by reactive oxygen species generation, NF-κB-mediated pro-inflammatory cytokine amplification, and mucosal barrier breakdown. Patients present with erythema progressing to painful pseudomembranous ulcerations causing severe dysphagia and nutritional compromise, frequently interrupting cancer therapies. Palifermin, a recombinant keratinocyte growth factor, is utilized to reduce severe mucositis incidence in hematological malignancy patients undergoing stem cell transplantation. Cryotherapy during short chemotherapy infusions reduces mucosal exposure, while photobiomodulation therapy using low-level laser irradiation has demonstrated consistent efficacy across guidelines to prevent and treat lesions. Symptomatic management has advanced past short-acting lidocaine rinses, which fail to deliver durable relief and carry systemic toxicity. The localized pain protocol relies on long-acting anesthetic formulations, led by oral bupivacaine lozenges (BupiZenge) that provide hours of targeted pain reduction to safely maintain swallowing and sleep without relying on systemic opioids. Rigid oral hygiene and multidisciplinary dental monitoring remain essential to preserve mucosal integrity and optimize cancer therapy compliance.

Key Highlights

• In Germany, diagnosed incident Oral Mucositis cases are projected to increase from 562,562 in 2025 to 602,105 by 2035.
• Oral Mucositis is a common complication of chemotherapy and radiotherapy, significantly impacting patient quality of life and treatment adherence.
• Severe cases may lead to treatment interruptions, increased infection risk, and higher healthcare costs.
• Significant unmet need remains for therapies that effectively prevent and manage oral mucosal injury.

Market Overview

• The Germany Oral Mucositis market is projected to grow from $55M in 2025 to $130M by 2035.
• Market growth is driven by:
• Increasing cancer incidence and use of intensive anticancer therapies
• Growing adoption of supportive care and novel preventive treatments
• Future growth will depend on therapies capable of preventing severe mucositis and improving treatment continuity.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• EpicentRx, Inc.
• OncoZenge AB
• MitoImmune Therapeutics

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)